HanchorBio Partners With InxMed to Expand HCB101 Oncology Pipeline

The collaboration centers on preclinical research pairing HCB101 with InxMed’s clinical-stage assets, specifically the FAK inhibitor ifebemtinib (IN10018) and the FAP-targeted antibody-drug conjugate OMTX705. While HanchorBio has primarily focused its CD47/SIRPα pathway candidate on gastric cancer, this partnership attempts to validate its utility as a broader combination backbone. InxMed provides specific expertise in tumor microenvironment biology, offering a potential gateway to address immune exclusion and fibrosis.

For investors, the agreement serves as a technical milestone rather than a financial catalyst, as no licensing fees or trial commitments were disclosed. The move aligns with HanchorBio’s "anchor-and-expand" strategy, which utilizes proven clinical settings to test whether their FBDB™ platform can translate into wider therapeutic applications. Success hinges on whether the resulting translational data can justify expanding HCB101’s clinical footprint into new, biologically distinct solid tumor indications.